Mode
Text Size
Log in / Sign up
N/A Completed N=76 Randomized Supportive Care

mHealth for Breast Cancer Survivors With Insomnia

Breast Cancer Survivor · Insomnia
Source: ClinicalTrials.gov NCT05233800 ↗
Enrolled (actual)
76
Serious AEs
0.0%
Results posted
Jan 2025
Primary outcomePrimary: Insomnia Symptoms — -8.4; -2.6 units on a scale — p=<0.05

Summary

The aim of this study is to determine the impact of the voice-activated smart speaker CBT-I components on insomnia symptoms among breast cancer survivors using a randomized clinical trial.

Outcome Measures

OutcomeResultp-value
PRIMARY
Insomnia Symptoms
-8.4; -2.6 <0.05 sig
SECONDARY
Six Week Change in Sleep Efficiency
0.09; 0.05
SECONDARY
Six Week Change in Wake After Sleep Onset
-18.6; -9.1
SECONDARY
Six Week Change in Sleep Onset Latency
-13.79; -5.46
SECONDARY
Six Week Change in Total Sleep Time
0.26; 0.27

Eligibility Criteria

Inclusion Criteria

  • Willingness to maintain a consistent dosing pattern if currently taking sleep medications or using cannabis for sleep
  • Females; Age 18+
  • Self-reported or documented diagnosis of breast cancer stage I-III or stage IV ECOG 0-1
  • Completed curative treatment (surgery, radiation, chemotherapy) > 3 months prior to enrollment [ongoing adjuvant therapy permitted]
  • Has not undergone other behavioral sleep treatment within the prior 12 months
  • Score greater than or equal to 8 on the Insomnia Severity Index
  • Able to understand and speak English

Exclusion Criteria

  • Diagnosed, untreated obstructive sleep apnea syndrome, narcolepsy, restless leg syndrome, periodic limb movement disorder, delayed sleep phase syndrome, central apnea
  • Bi-polar disorder, schizophrenia, initiation of psychological treatment within three months, alcohol or drug abuse in the prior year (Alcohol >2 drinks/day or consuming 5+ drinks in a single day in the prior month). (Moderate ADHD, depression and anxiety will not be exclusion criteria.)
  • Shift-work in the prior three months or anticipated during the study time
  • Planned regular travel out of time zone (>1 hour) during the study period.
  • Currently or planning to become pregnant during the study period
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05233800). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.

Back to search